Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue $ 108 $ 0 $ 433 $ 0
Cost of goods sold 38 0 199 0
Gross profit 70 0 234 0
Operating expenses:        
Research and development 1,315 4,911 4,248 15,556
General and administrative 6,505 8,165 20,256 32,629
Depreciation and amortization 51 24 142 67
Total operating expenses 7,871 13,100 24,646 48,252
Loss from operations (7,801) (13,100) (24,412) (48,252)
Other income (expense):        
Interest income, net 1 2 2 45
Gain on settlement of debt 553 0 553 0
Loss on foreign currency translation 0 0 0 (1)
Loss before income taxes (7,247) (13,098) (23,857) (48,208)
Income taxes (benefit) 0 0 0 0
Net loss (7,247) (13,098) (23,857) (48,208)
Non-controlling interest (6) 1,696 584 6,282
Net loss attributable to BioSig Technologies, Inc. (7,253) (11,402) (23,273) (41,926)
Preferred stock dividend (2) (2) (7) (11)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (7,255) $ (11,404) $ (23,280) $ (41,937)
Net loss per common share, basic and diluted (in Dollars per share) $ (0.21) $ (0.38) $ (0.71) $ (1.56)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 34,856,502 29,750,378 32,881,932 26,900,383
Product [Member]        
Revenue $ 100 $ 0 $ 414 $ 0
Service [Member]        
Revenue $ 8 $ 0 $ 19 $ 0